About this trial
This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions.
Patient Profile
Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
Where’s this trial being run?
St James’s Hospital and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | INDEPENDENCE ACE-536-MF-002 |
|---|---|
| Number: | 20-34 |
| Full Title: | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions |
| Principal Investigator: | Dr Clodagh Keohane |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Celgene/Bristol-Myers Squibb |
| Recruitment Started: |
Global: 11-Mar-21 Ireland: 24-May-21 |
| Global Recruitment Target: | Approx. 390 patients |
|---|---|
| Ireland Recruitment Target: | 1-2 patients per site |